Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hemophilia A.

J M Lusher1, I Warrier

  • 1Division of Hematology/Oncology, Children's Hospital of Michigan, Detroit.

Hematology/Oncology Clinics of North America
|October 1, 1992
PubMed
Summary
This summary is machine-generated.

Advances in hemophilia A research offer new hope. Safer treatments, early prophylaxis, and gene therapy are emerging, though challenges like infections and inhibitors remain.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Complications of haemophilia in babies (first two years of life): a report from the Centers for Disease Control and Prevention Universal Data Collection System.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Types of bleeding seen during the first 30 months of life in children with severe haemophilia A and B.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Considerations for current and future management of haemophilia and its complications.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Factor IX inhibitors and anaphylaxis in haemophilia B.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Use of central venous catheters in children with haemophilia: one haemophilia treatment centre experience.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Factor IX inhibitors and anaphylaxis in hemophilia B.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same journal

Palliative Therapy for Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Ablative Therapies for Liver Tumors.

Hematology/oncology clinics of North America·2026
Same journal

Pathology of Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery for Liver and Biliary Tract Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Surgical Considerations for Primary Liver Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Systemic Therapy for Biliary and Liver Neoplasms: Chemotherapy and Immunotherapy.

Hematology/oncology clinics of North America·2026
See all related articles

Area of Science:

  • Hematology
  • Genetics
  • Medical Technology

Background:

  • Significant progress in understanding hemophilia A genetics.
  • Improved carrier detection and prenatal diagnostic methods.
  • Development of safer clotting factor concentrates.

Purpose of the Study:

  • To review recent advances in hemophilia A treatment and management.
  • To discuss the potential of new therapeutic strategies.
  • To highlight ongoing challenges in hemophilia care.

Main Methods:

  • Review of scientific literature and clinical trial data.
  • Analysis of emerging technologies in hemophilia A.
  • Discussion of future therapeutic directions.

Related Experiment Videos

Main Results:

  • Recombinant Factor VIII (FVIII) shows safety and efficacy in trials, nearing licensure.
  • Prophylactic therapy initiated in early childhood is being considered to prevent joint disease.
  • Gene insertion therapy for hemophilia A is a realistic possibility for the 1990s.

Conclusions:

  • Recent scientific and clinical advances mark an exciting era for hemophilia A.
  • Despite challenges including viral infections and inhibitors, new technologies offer significant hope.
  • A new decade presents both opportunities and challenges for hemophilia management.